Abstract
Reversine, an A3 adenosine receptor antagonist, has been shown to induce differentiated myogenic-lineage committed cells to become multipotent mesenchymal progenitor cells. We and others have reported that reversine has an effect on human tumor suppression. This study revealed anti-tumor effects of reversine on proliferation, apoptosis and autophagy induction in human non-small cell lung cancer cells. Treatment of these cells with reversine suppressed cell growth in a time- and dosage-dependent manner. Moreover, polyploidy occurred after reversine treatment. In addition, caspase-dependent apoptosis and activation of autophagy by reversine in a dosage-dependent manner were also observed. We demonstrated in this study that reversine contributes to growth inhibition, apoptosis and autophagy induction in human lung cancer cells. Therefore, reversine used as a potential therapeutic agent for human lung cancer is worthy of further investigation.
Highlights
Lung cancer is the most common cause of cancer-related death worldwide, and has been classified as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)
Reversine could inhibit the numbers of colony formations in the two cells (Fig 2). These data demonstrated that reversine could suppress cell growth and tumor formation in vitro in human NSCLC cells
Reversine has been demonstrated to be an inhibitor of Aurora kinases (Aur) [5], and it has been reported that Aur regulate mitosis [13], so we further investigated whether reversine could influence Aurora kinase-A (Aur-A) and B in human NSCLC cells
Summary
Lung cancer is the most common cause of cancer-related death worldwide, and has been classified as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for 75–80% of primary lung cancer patients. The biologic and clinical features of SCLC are considered different with other lung cancers. SCLC exhibits aggressive behavior, and is the most malignancy of various lung cancers [1,2,3]. Surgery is the most effective therapeutic modality to achieve a cure, but the postoperative prognosis is poor. Recrudesce and disease progression may appear quickly in NSCLC and SCLC patients, and the prognosis is poor [2, 3]. A novel and effective treatment modality is urgently needed for both SCLC and NSCLC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
